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The outcome of drug therapy is often unpredictable, ranging from beneficial effects to lack of 
efficacy to serious adverse effects. Variations in single genes are 1 well-recognized cause of such 
unpredictability, defining the field of pharmacogenetics (see Glossary). Such variations may 
involve genes controlling drug metabolism, drug transport, disease susceptibility, or drug targets. 
The sequencing of the human genome and the cataloguing of variants across human genomes are 
the enabling resources for the nascent field of pharmacogenomics (see Glossary), which tests the 
idea that genomic variability underlies variability in drug responses. However, there are many 
challenges that must be overcome to apply rapidly accumulating genomic information to 
understand variable drug responses, including defining candidate genes and pathways; relating 
disease genes to drug response genes; precisely defining drug response phenotypes; and 
addressing analytic, ethical, and technological issues involved in generation and management of 
large drug response data sets. Overcoming these challenges holds the promise of improving new 
drug development and ultimately individualizing the selection of appropriate drugs and dosages 
for individual patients.
The concept that genetic variation contributes to variability in disease phenotypes and in 
drug responses is widely accepted and validated in many research settings. For some drugs, 
there are clear implications of genetic information for drug therapy to avoid toxicity and to 
optimize response (1, 2). In addition, understanding genetic contributors to variability in 
drug response provides a new tool in drug development that carries the hope of decreasing 
the risk for unexpected toxicities, identifying patients most likely to respond, and 
streamlining drug development (3).
The English physiologist Archibald Garrod (4) proposed that similar genetic factors might 
underlie inborn errors of metabolism and variable responses to drugs. The field of 
pharmacogenetics developed after variant drug responses due to large single gene effects 
were described (1, 5–8), as Garrod suggested. Genetic science is now increasingly turning its 
attention to how variation in large gene sets, in complex biological pathways (see Glossary), 
or in the whole genome, contributes to variable phenotypes, such as disease susceptibility 
(9). This evolution from genetics to genomics is paralleled by progress in understanding the 
genetic contribution to variable drug responses, from pharmacogenetics to 
pharmacogenomics (Table 1) (Figure 1). This review will outline progress in the field by 
describing mechanisms underlying variable drug responses, the potential role of genetic 
factors in their causes, and contemporary and evolving approaches to identifying these 
genetic factors. Examples are presented throughout, although it is not our goal to review 
these in a comprehensive fashion; rather it is our intent to identify the challenges that must 
be overcome and their potential solutions if genetic and genomic information is to be 
integrated into drug prescribing.
Mechanisms Underlying Variable Drug Responses
Clinicians and the lay public accept the notion that not all patients respond to drug therapy 
in the same fashion. An overarching challenge in contemporary therapeutics is to define the 
mechanisms underlying such variability. Occasionally, the distribution of drug responses 
across a population is clearly bimodal, suggesting a predominant role for a single variable 
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that is often genetic (Figure 2, top). More commonly, drug responses in patient populations 
show a broad distribution (Figure 2, bottom). Studies with twins done as early as the 1960s 
support the idea that this pattern of responses may also include a prominent genetic 
component (12–14).
Two distinct processes, either of which can be influenced by genetic factors, underlie the 
generation of a clinical drug action: delivery to and removal from target sites in plasma on 
cell surfaces, or within cells (pharmacokinetics) (see Glossary) and interaction with the 
targets to generate a cellular effect that is translated to clinical effect (pharmacodynamics). 
Thus, the starting point for many contemporary pharmacogenetic studies is identification of 
variable drug responses in an individual patient or across a population. Then, an 
understanding of the underlying pharmacokinetics or pharmacodynamics can be used to 
identify individual candidate genes (see Glossary) in which variant function may “explain” 
the variable drug response. An alternate approach, to interrogate many candidate genes or 
even the whole genome (see Glossary), has emerged more recently and will be discussed 
further.
Genetically Determined Pharmacokinetics
Some of the earliest findings in pharmacogenetics involve variations in single genes 
encoding drug-metabolizing enzymes, which can underlie aberrant responses to substrate 
drugs (Table 2). The highest likelihood of aberrant drug responses occurs when genetically 
determined reduced function of 1 drug elimination pathway is coupled with the absence of 
alternate pathways that can readily subserve the same function (15). Individual cases were 
first identified in patients with clinically dramatic phenotypes (see Glossary) because these 
patients were homozygous (see Glossary) for loss of function in such alleles (see Glossary).
Coding-Region Variants
Changes in DNA sequence that occur in regions that encode protein may lead to changes in 
the primary amino acid sequence and protein function. A well-studied example that is 
entering routine clinical practice is the thiopurine methyltransferase (TPMT) gene, whose 
protein product is responsible for bioinactivation of thiopurines, such as azathioprine or 
mercaptopurine (1, 16, 17). Rare individuals who are homozygous for loss of function 
variants are at high risk for bone marrow aplasia during therapy with standard doses, and 
this is stated in the package label. Ten percent of persons carry a single abnormal allele and 
are also at increased risk for bone marrow toxicity (18, 19). Conversely, “standard” doses of 
mercaptopurine that are used in the 90% of patients with functional alleles mutations (see 
Glossary) may in fact be inadequate for achieving an optimal antileukemic effect (20).
The most common mechanism for drug elimination is metabolism by members of the 
cytochrome P450 (CYP) superfamily. Common coding-region CYP variants that affect drug 
elimination and responses have now been described. The frequency of many variants varies 
by ethnicity, and this may be one factor determining ethnic-specific drug responses. Up to 
10% of white and African-American persons are homozygous for loss of activity of a 
cytochrome P450 isoform, which is termed CYP2D6. Persons with this poor-metabolizer 
genotype have drug accumulation and increased side effects with some antidepressants (21). 
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In addition, persons who are poor metabolizers do not metabolize codeine to its active 
metabolite morphine and thus have reduced analgesia (22). An important implication of the 
identification of highly variable CYP2D6 activity is that new drug candidates that are 
eliminated predominantly by this enzyme are often not further developed (23, 24). In 
contrast to CYP2D6, the poor metabolizer trait for a different CYP, CYP2C19, is more 
common in Asian persons, and persons with this genotype have higher drug concentrations 
and a greater cure rate of Helicobacter pylori infections during therapy with the CYP2C19 
substrate omeprazole (25).
DNA Variants in Noncoding Regions
Only a small fraction of the human genome encodes proteins. One important role of 
noncoding DNA is to regulate the amount of messenger RNA (mRNA) transcribed, and thus 
protein generated, in the basal state or in response to many environmental stimuli. Sequence 
variants in regulatory regions that result in altered amounts of otherwise normally 
functioning protein can underlie abnormal drug responses. A good example is the repeat 
polymorphism (see Glossary) in the promoter of UGT1A1, which encodes the 
glucuronosyltransferase responsible for conjugation of bilirubin and many drugs. The most 
common hypofunctional allele, termed UGT1A1*28, is an insertion of 2 extra base pairs 
(TA) in a key regulatory region of the gene, resulting in decreased protein expression. 
Impaired elimination of bilirubin by this mechanism is the cause of the Gilbert syndrome. 
UGT1A1 is responsible for the metabolism of SN-38, the active metabolite of the anticancer 
drug irinotecan, and persons who are homozygous for UGT1A1*28 are at increased risk for 
serious adverse effects of the drug (26). This effect is of sufficient clinical importance that it 
is now described on the irinotecan product label (27, 28). Commercial tests for variants in 
TPMT, CYP2D6, CYP2C19, and UGT1A1 are now available (29).
Variable Drug Transport
Drug entry into and removal from cells are often active processes, accomplished by specific 
drug transport molecules (30, 31), and variants in the genes encoding these transporters have 
been implicated in variable drug responses. Thus, normal function of the drug efflux 
transporter P-glycoprotein is required for the biliary excretion of digoxin, and a common P-
glycoprotein polymorphism has been associated with variable serum digoxin (32, 33). 
Similarly, polymorphisms in an organic anion (uptake) transporter have been implicated in 
the efficacy and some adverse effects of statins (34).
Genetically Determined Pharmacodynamics
Variability in the Genes Encoding Drug Targets
Drugs can produce highly variable effects, even in the absence of substantial variability in 
drug concentrations at target sites. This pharmacodynamic variability tends to be drug- or 
disease-specific, in contrast to pharmacokinetic variability that often extends across many 
drugs and disease processes. One obvious set of genes in which variants might account for 
such pharmacodynamic variability is those encoding drug targets. Thus, a plausible 
candidate gene for modulating variability in response to β2-agonists in asthma is the β2-
receptor, and such variants in this gene have been reported (35).
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Variants in multiple genes can contribute to variable drug actions, and recent studies with 
warfarin are an excellent example. Previous work had identified variable metabolism by 
CYP2C9 as a major contributor to variable responses to the drug (36). In 2004, coding-
region mutations in VKORC1, encoding a subunit of the vitamin K epoxide reductase 
complex (the pharmacologic target for the drug), were found to cause a rare syndrome of 
warfarin resistance (37). Subsequently, common variants in VKORC1 have been found to 
account for a much greater fraction of variability in warfarin response (21%) than do 
variants in CYP2C9 (6%) (38). The CYP2C9 variants are in the coding region and alter 
enzyme activity, whereas the VKORC1 variants are noncoding and are thought to alter 
expression of the protein. The mechanisms underlying the remaining variability in warfarin 
effect have not been elucidated.
Variability in the Biological Context in Which Drugs Act
Variability in drug actions may reflect genetically determined changes not only in 
metabolism or in the drug target but also in the complex biological milieu in which drugs 
interact with their target molecules. An example that has received considerable attention is 
drug-induced prolongation of the QT interval and susceptibility to the ventricular 
tachycardia torsades de pointes, a common cause for drug withdrawal or relabeling (39). 
Although the length of the QT interval is determined by many ion-channel and other genes, 
only 1 (HERG [KCNH2]) is the target for QT-prolonging drugs; as a consequence, new drug 
candidates are now routinely screened for KCNH2-blocking activity (40). Of importance, 
surveys of patients with drug-induced torsades de pointes occasionally identify predisposing 
mutations not only in the drug target (the KCNH2 channel) but also in other genes that 
control the QT interval (41, 42); that is, variability in the physiologic control of the QT 
interval can contribute to variable effects of KCNH2 blockers.
Defining Drug Response
A key first step in any pharmacogenetic study, and indeed in all contemporary translational 
medicine, is precisely defining responders and nonresponders to therapy. Failure in this 
effort ensures failure for any subsequent genetic analysis. There is as much tension between 
well-defined clinical (often termed “hard”) end points, such as death, and biomarkers and 
surrogate end points, such as altered tumor size, change in blood pressure, or altered serum 
concentration of a disease-related protein, in pharmacogenetics as there is in all translational 
research. To the extent that biomarkers and surrogate end points can serve as relevant 
“intermediate phenotypes” that define important subsets of disease or drug responses, their 
definition is a critical component of minimizing confounding variables in any genetic-based 
analysis. A related challenge is the informatics problem of developing uniform methods to 
represent phenotypic data, such as drug responses, as is now the case with relatively 
standardized methods for representing genetic sequence and variation data.
Evolving Approaches to Identify Genes That Modulate Drug Responses
One approach in contemporary pharmacogenetics is to first use an understanding of 
pharmacokinetics and pharmacodynamics (see Glossary) to identify candidate genes that 
may determine the action of a drug. Then, the candidate genes are screened for variants, and 
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the variants are screened for biological activity. This “genotype to phenotype” approach can 
lead not only to associations (see Glossary) between functional variants and drug responses 
but also to new insights into the basic biology of these proteins (43, 44). The converse 
strategy, “phenotype to genotype,” first defines variable drug response phenotypes and then 
searches in single genes, in pathways, or across the genome for sources of that variability.
Initial studies in pharmacogenetics often focused on small numbers of drug response 
outliers, studying candidate genes identified on the basis of an understanding of the 
underlying physiology and culminating in identification of variants associated with the 
outlier phenotype. This approach is intuitively appealing, especially if variants display 
abnormal function in vitro or in animal models that could plausibly explain the outlier drug 
response phenotype. CYP2D6, UGT1A1, and KCNH2 variants that mediate unusual 
responses to drug therapy are examples of this approach. Outlier drug responses that may 
lend themselves to such a strategy include the problems of rare and clinically severe adverse 
drug reactions, such as torsades de pointes, the lupus reaction, or hepatotoxicity (39, 45). 
Because these reactions often occur in an apparently unpredictable fashion, they have been 
termed “idiosyncratic,” and a genetic predisposition is often invoked. Accrual of patient sets 
in which to test this idea will require multi-center collaborations (46), and the initial focus of 
genetic analysis has been on a small number of genes chosen because they may be 
associated with disease susceptibility (41, 42, 47–50).
Disease Phenotypes
An obvious potential mechanism underlying variability in therapy for such common diseases 
as cancer, arrhythmia, or asthma is that these phenotypes represent an overlapping spectrum 
of mechanistically distinct diseases at the molecular or genetic level (51–53). In some cases, 
understanding the basis for a monogenic disease can inform and rationalize drug therapy; 
thus, mutations in KCNJ11, a component of a sulfonylurea-sensitive potassium channel, 
cause neonatal diabetes that is especially sensitive to sulfonylureas (54, 55). Disease-
associated genetic variants (see Glossary) may be inherited (present in the germline) or arise 
later; such somatic cell mutations are often found in cancer, where they may arise as a 
consequence or a cause of disease and may contribute to variability in drug response. The 
epidermal growth factor receptor inhibitors gefitinib and erlotinib display highly variable 
responses in lung cancer, and dramatic tumor shrinkage now seems to be characteristic of a 
small group of patients whose tumors have somatic mutations in the tyrosine kinase domain 
of the receptor (56, 57). A screening test to identify such responders has now been 
commercialized (58).
Another example of the relationship between disease and drug response genetics is shown 
by a large study that implicated specific alleles in the 5-lipoxygenase gene as risk factors for 
myocardial infarction and stroke (59). On the basis of this finding, drugs to inhibit the 5-
lipoxygenase–activating protein have been developed, and the first trial studied only patients 
selected for the at-risk genetic variant (60). This study paradigm shows how screening very 
large gene sets, up to the whole genome, can inform new biology and drug development, an 
advantage that the candidate gene approach generally lacks.
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Although the approach of analyzing candidate genes has considerable intuitive appeal, it 
suffers from the criticism that it fails to consider a potential contribution of other genes, 
including those whose function is not yet well understood. Increasingly robust technologies 
are being developed to interrogate sets of single-nucleotide polymorphisms (SNPs) across 
the entire genome, and such whole genome association approaches have been applied to 
identify new disease susceptibility genes and pathways (61–63). This “unbiased” whole 
genome approach may also be applicable to the problem of identifying new loci-modulating 
variability in drug response.
Comparing the frequencies of hundreds of thousands of polymorphisms in patients with or 
without a specified genotype (see Glossary) will inevitably generate a very large number of 
false-positive associations. Thus, one way to interpret genome-wide association studies is 
that they may be able to identify genomic loci, which can then be studied in other patient 
subsets (that is, they are hypothesis-generating tools). Despite the very large number of 
polymorphisms in the human genome, it has also become apparent that these are not 
independent. Knowledge of the genotype at 1 locus informs genotype at other loci that are in 
linkage disequilibrium (64). The definition of such haplotype (see Glossary) structure across 
the genome and of “tag SNPs” that can thereby provide genotype information at multiple 
loci is a major goal of ongoing studies within industry and at the international HapMap 
consortium (65, 66). Such information will in turn be an enabling resource for large-scale 
genome-wide association studies by reducing the number of SNP sites for study.
The Concept of Drug Response “Pathways”
An appealing intermediate step between the single candidate gene approach and the nascent 
genome-wide approach is to consider that variable disease and drug response phenotypes 
reflect perturbations in function of increasingly well-characterized physiologic systems 
comprising dozens or hundreds of interacting gene products. Thus, studies of response to 
corticosteroids or β2-agonists in patients with asthma consider variations not only in 
corticosteroid or β2-adrenergic receptors but also in the downstream and interacting 
signaling pathways they modulate. In 1 such study, genotyping at 131 SNP sites in 14 genes 
in the steroid pathway identified and subsequently reproduced an association between 
response to inhaled steroids in asthma and polymorphisms in the type 1 corticotrophin-
releasing hormone receptor (67). This identifies a new predictor of drug response and 
suggests that this receptor could be a target for new drug development. Similarly, screening 
145 polymorphisms in 5 candidate ion-channel genes has identified a noncoding region in a 
potassium-channel gene as a potential contributor to risk for torsades de pointes (68). 
Screening 148 polymorphisms in 10 genes involved in cholesterol control identified non-
coding variants in the 3-hydroxy-3-methylglutaryl coenzyme A reductase gene-modulating 
response to statin drugs that interact with this gene product (69). One advantage of this 
approach is that the number of rationally chosen candidate genes is markedly expanded but 
remains technologically and computationally tractable. In addition, increasingly 
sophisticated computational techniques are evolving to analyze how the behavior of a 
complex biological system changes in response to variable function of an individual 
component (70, 71).
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Moving to Clinical Practice
An increasingly sophisticated understanding of the relationship between genetic variants and 
variability in drug response has identified and highlighted many important obstacles that 
must be overcome if this approach is to enter and enrich clinical practice.
Design and Interpretation of Pharmacogenetic and Pharmacogenomic Studies
Identification of an association between a clinical phenotype, such as drug response, and a 
genetic variant or a set of genetic variants is an increasing theme in the medical literature. 
However, many such associations were not reproduced in subsequent studies (72, 73); false-
positive associations are one common reason. Another reason may be subtle differences in 
patient study groups, such as ethnicity or definition of end points. Thus, similar to other 
diagnostic approaches, pharmacogenetic testing will be implemented only when its 
predictive value is established.
Regulatory Issues in Genetic Testing
Questions regarding regulatory issues include mechanisms for regulating genotyping tests, 
the extent to which pharmacogenetic analyses should be incorporated into new drug 
development before or after large clinical trials, and whether and how pharmacogenetic 
information can be incorporated into the product labels that inform clinicians and patients. 
The U.S. Food and Drug Administration has launched an initiative to collect 
pharmacogenetic information during drug development that may help address some of these 
issues (74, 75); in addition, as already discussed, some drug labels have been changed to 
include pharmacogenetic information.
Development of New Genomic Technologies
Delivery of reliable genetic information to the clinician for decision making requires very 
rapid turn-around, or a setting in which drug therapy can be reasonably initiated after the 
results of a genetic test are available (for example, in chronic disorders, such as 
hypertension). Technology in this area is evolving very rapidly. A third scenario, in which an 
individual patient's whole genome is sequenced and available for decision making, seems 
likely within 5 to 10 years. This will require whole genome sequencing for less than several 
thousand dollars, appropriate information management systems, and new genomic statistical 
analysis approaches.
Ethical Issues
Identification of genetic variants associated with altered pathophysiology has raised 
questions of whether individuals or groups enriched for such genetic variants could be 
stigmatized (for example, by being denied insurance) (76, 77).
Education
The human genome is a new resource, and considerable education will be required to apply 
its promise in practice (78). Even for common and well-defined genetic variants with 
reproducible and important consequences for disease or drug therapy, wide acceptance by 
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the medical community has been slow. This may reflect failure of education or lack of clear-
cut studies showing added clinical value to understanding genetic information before 
prescribing drugs. Increasing educational efforts for the medical and lay communities will 
be required to understand the advantages and limitations of new genome-based clinical data.
Cost
One reason for slow adoption of pharmacogenetic testing is that data on cost-effectiveness 
are limited. This is obviously a complex issue that relates not only to the cost of genotyping 
itself but also to competing costs, such as those of caring for a patient with a catastrophic 
and predictable complication of drug therapy. Of note, however, a genotype needs to be 
established only once in a lifetime, and the costs of currently available tests are often less 
than those of the drugs themselves.
The Pharmacogenetics Research Network
Work toward overcoming the challenges described here has identified and highlighted 
specific obstacles in generating high-quality pharmacogenetic information and moving it 
from the research to the clinical setting and has, in some cases, pointed the way to solutions. 
Recognizing the challenges and the promise of pharmacogenetics, the National Institutes of 
Health initiated the Pharmacogenetics Research Network in 2000, with 3 overall goals: 1) to 
investigate the relationship of genetic variation to variable drug response; 2) to become an 
interactive network of investigators that impacts and elevates the field of pharmacogenetics 
with knowledge, tools, and resources; and 3) to create a publicly available knowledge base 
with reliable information that links phenotypes to genotypes. This knowledge base is 
available at www.pharmgkb.org and represents a central Web-enabled repository of variants 
in genes determining drug responses, their relationship to drug response phenotypes, and the 
strength of the evidence linking the two. This Web site is not only a repository but also a test 
bed that may enable advances in such areas as discovery of new associations or improved 
representations for drug response phenotypes.
Summary
Although the concept of pharmacogenetics, 1 allele at a time, was first proposed over a 
century ago, the more recent term pharmacogenomics captures the essence of contemporary 
work in this field. In addition to studying single allelic variants with large clinical effects, 
investigators are beginning to explore much larger sets of genes, including pathways up to 
the whole genome, and how variations in these pathways may affect drug response.
Pharmacogenomics is a young field that holds considerable promise of contributing to our 
understanding of the mechanisms underlying variability in human physiology and its 
response to drug therapy, with the potential to improve therapy. Indeed, studies in the field 
have discovered new biological mechanisms and have identified certain molecules, such as 
CYP2D6 or KCNH2, that are now routinely considered in drug development to enhance 
drug safety and are identifying new targets for drug action. Ultimately, identification of 
DNA variants before prescribing medication may become a routine feature of any patient–
physician encounter. Although there are many challenges to be overcome in the 
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implementation of pharmacogenetic vision in clinical practice, potential solutions are also 
evolving rapidly.
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Glossary
Alleles Alternate sequences of the same gene, 1 inherited from 
each parent.
Association A statistical finding that the frequency of 1 or more genetic 
variants is significantly different in patients with a 
phenotype than in those without the phenotype. Often 
polymorphisms in candidate genes are studied. A more 
recent method, whole genome association, seeks to identify 
new genes involved in variable phenotypes; the technique 
uses new methods to compare genotypes at hundreds of 
thousands of polymorphic sites in large numbers of patients 
with and without a specific phenotype.
Biological pathway A set of proteins that interact to produce normal and 
abnormal physiology.
Candidate gene A gene in which variants could plausibly explain a given 
phenotype, such as severity of disease or variable response 
to drug. Methods to identify candidate genes include basic 
science studies, identifying DNA sequences conserved 
across species, human genetics, or genome-wide analyses. 
Candidate genes may be in pharmacokinetic or 
pharmacodynamic pathways.
Genome The collection of all DNA in an organism. Only a small 
proportion (probably <3%) of human genomes encodes 
proteins.
Genetic variant A difference in DNA sequence compared with a reference 
sequence.
Genotype The genetic makeup of an individual, which may refer to 
the whole genome or to specific genes or regions of genes.
Haplotype A set of genetic variants that are inherited together. 
Polymorphisms that are co-inherited more often than by 
chance alone are in linkage disequilibrium. Haplotype 
blocks may include many individual polymorphisms in 
high linkage disequilibrium; as a result, establishing 
genotype at any single polymorphic site with such a block 
may establish genotypes at linked sites within the block. 
Individual single-nucleotide polymorphisms (SNPs) that 
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can be used to establish genotype within a haplotype block 
are termed tag SNPs.
Homozygous The same alleles in a specific region of DNA.
Mutation Rare variants, most often in coding regions, which are 
often associated with genetic diseases, such as cystic 
fibrosis or sickle cell anemia.
Pharmacodynamics The study of the relationship between drug concentrations 
and drug effects.
Pharmacogenetics The study of the relationship between individual gene 
variants and variable drug effects.
Pharmacogenomics The study of the relationship between variants in a large 
collection of genes, up to the whole genome, and variable 
drug effects.
Pharmacokinetics The study of the relationship between drug dose and drug 
concentrations (often as a function of time) in plasma or 
tissue.
Phenotype Measurable characteristics of an organism. These may 
derive from genotype, environment, or their combination. 
Organisms with the same phenotype can have different 
genotypes.
Polymorphisms DNA variants that are common, often defined as greater 
than 1% in a given population (although rare 
polymorphisms are increasingly being recognized). 
Polymorphisms can be in coding regions (where they may 
synonymous or nonsynonymous) or, more commonly, in 
noncoding regions, and often vary by ethnicity. The most 
common type of polymorphism is a change in 1 nucleotide 
(base pair) in a DNA sequence, referred to as an SNP. 
Other polymorphisms are insertion and deletion of multiple 
sequential nucleotides (“indels”); variable numbers of 
repeats, such as doublets or triplets; or large-scale 
duplications or deletions. Although some genetic variants 
are known to alter protein abundance or function, the 
functional consequences of most polymorphisms are 
unknown.
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Figure 1. The concept of pharmacogenetics
Pharmacogenetics focuses on large clinical effects of single gene variants in small numbers 
of patients. However, the concept of pharmacogenomics examines many genomic loci, 
including large biological pathways and the whole genome, to identify variants that together 
determine variability in response to drug therapy.
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Figure 2. Two types of variability in drug action
Top. Volunteers received 10 mg of the CYP2D6 substrate debrisoquine, and the ratio of 
urinary concentrations of the parent drug and its 4-hydroxy metabolite in urine were 
determined. This experiment identifies at least 2 distinct populations, extensive and poor 
metabolizers, separated at the antimode (arrow). Redrawn with permission from reference 
10. Bottom. Change in FEV1 in 1117 participants in 3 different trials of antiasthmatic 
therapy (inhaled steroids). Although the responses vary markedly, from an apparently 
deleterious drug effect to a highly beneficial one, there is no antimode. Redrawn with 
permission from reference 11.
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Establishing that drug responses are heritable Twin studies; family studies
Linkage between drug response and genomic loci in cell lines, or model 
organisms
Defining candidate genes Pharmacokinetic
Pharmacodynamic
 Drug targets
 Biological milieu in which drugs act
Disease genes and pathways
Whole genome approaches
Defining drug responses Biomarkers
Surrogates
“Hard” end points
Data management, including uniform representation of 
phenotypic data
Improved informatics




Statistical analysis of associations New statistical methods, including consideration of haplotypes
Interrogating very large sets of polymorphisms in large numbers 
of patients
New platforms (e.g., chip- or bead-based)
Moving to practice Reproducible study results
Cost-effectiveness
Health care provider education
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Table 2
Examples of Associations between Drug Response and Genetic Variants*
Drug Variable Clinical Effect Genes with 
Associated Variants
Possible Mechanism
Azathioprine and mercaptopurine Bone marrow aplasia TPMT Hypofunctional alleles
Reduced therapeutic effect at 
standard doses
Wild-type alleles
Some antidepressants and β-blockers Increased side effect risk CYP2D6 Hypofunctional alleles
Decreased efficacy Gene duplication
Omeprazole Helicobacter pylori cure rate CYP2C19 Hypofunctional alleles
Irinotecan Neutropenia UGT1A1 Decreased expression due to regulatory 
polymorphism
HIV protease inhibitors Central nervous system levels MDR1 Altered P-glycoprotein function
β-blockers Blood pressure lowering and 
heart rate slowing
ADRB1 Altered receptor function or number
Inhaled β2-agonists Bronchodilation ADRB2 Altered receptor function or number
Diuretics Blood pressure lowering ADD1 Altered cytoskeletal function by adducin 
variants
Warfarin Anticoagulation VKORC1 Variant haplotypes in regulatory regions 
leading to variable expression
CYP2C9 Coding region variants causing reduced S-
warfarin clearance
Abacavir Immunologic reactions HLA variants Altered immunologic responses
QT-prolonging antiarrhythmics Drug-induced arrhythmia Ion-channel genes Exposure of subclinical reduction in 
repolarizing currents by drugs
General anesthetics Malignant hyperthermia RYR1 Anesthetic-induced increased release of 
sarcoplasmic reticulum calcium by mutant 
channels
Inhaled steroids Bronchodilation CRHR1 Unknown




HMGCR Altered HMG-CoA reductase activity
*
ADD1 = the gene encoding α-adducin; ADRB1 = the gene encoding the β1-adrenergic receptor; ADRB2 = the gene encoding the β2-adrenergic 
receptor; CRHR1 = the gene encoding corticotrophin-releasing hormone receptor-1; CYP2C19 = the gene encoding the 2C19 cytochrome P450 
isoform; CYP2C9 = the gene encoding the 2C9 cytochrome P450 isoform; CYP2D6 = the gene encoding the 2D6 cytochrome P450 isoform; 
HMG-CoA = 3-hydroxy-3-methylglutaryl coenzyme A; HMGCR = the gene encoding HMG-CoA reductase; MDR1 = the gene encoding P-
glycoprotein; RYR1 = the gene encoding the skeletal muscle calcium-release channel; TPMT = the gene encoding thiopurine methyltransferase; 
UGT1A1 = the gene encoding uridine diphosphate glycosyltransferase 1 family, polypeptide A1; VKORC1 = the gene encoding vitamin K epoxide 
reductase complex, subunit 1.
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